Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7156 to 7170 of 7675 results

  1. Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

    This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

    Technology appraisal guidance
    Published
    26 April 2017

  2. Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 674. People already taking pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their doctor decide when best to stop.

    Technology appraisal guidance
    Published
    13 June 2018

  3. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Technology appraisal guidance
    Published
    24 October 2002

  4. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

    This guidance has been updated and replaced by NICE technology appraisal guidance 783.

    Technology appraisal guidance
    Published
    14 March 2018

  5. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Technology appraisal guidance
    Published
    21 March 2018

  6. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Technology appraisal guidance
    Published
    1 November 2017

  7. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Technology appraisal guidance
    Published
    1 November 2017

  8. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Technology appraisal guidance
    Published
    8 November 2017

  9. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

    This guidance has been updated and replaced by NICE technology appraisal guidance 692.  

    Technology appraisal guidance
    Published
    25 April 2018

  10. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

    This guidance has been updated and replaced by NICE technology appraisal guidance 870.

    Technology appraisal guidance
    Published
    7 February 2018

  11. Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

    We have withdrawn this guidance. Grünenthal has stopped marketing Lesinurad (Zurampic) for commercial reasons and its marketing authorisation has been withdrawn.

    Technology appraisal guidance
    Published
    7 February 2018

  12. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

    This guidance has been updated and replaced by NICE technology appraisal guidance 736.

    Technology appraisal guidance
    Published
    22 November 2017

  13. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    This guidance has been updated and replaced by NICE technology appraisal guidance 795.

    Technology appraisal guidance
    Published
    22 November 2017

  14. Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

    This guidance has been updated and replaced by NICE technology appraisal guidance 739.

    Technology appraisal guidance
    Published
    6 December 2017

  15. Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

    This guidance has been updated and replaced by NICE technology appraisal guidance 616.

    Technology appraisal guidance
    Published
    6 December 2017